摘要
目的分析西洛他唑联合替格瑞洛治疗老年急性心肌梗死患者的临床效果。方法选取2020年6月至2021年6月辽宁省金秋医院收治的老年急性心肌梗死患者80例,采用抽签法随机分为观察组与对照组,每组40例。所有患者均接受经皮冠状动脉介入及替格瑞洛治疗,对照组在此基础上联合阿司匹林治疗,观察组在此基础上联合西洛他唑治疗,比较两组患者治疗前后的心功能指标(左心室舒张末期内径、左心室收缩末期内径、左心室射血分数)、超敏C反应蛋白水平、脂蛋白(a)水平和血脂指标(总胆固醇、甘油三酯、低密度脂蛋白、高密度脂蛋白),以及治疗期间不良反应、主要不良心血管事件、出血事件发生情况。结果与治疗前比较,两组患者治疗后左心室舒张末期内径、左心室收缩末期内径和超敏C反应蛋白水平、脂蛋白(a)水平明显下降,且观察组明显低于对照组,而左心室射血分数明显升高,且观察组明显高于对照组,差异均有显著性(P<0.05)。两组患者治疗后总胆固醇、甘油三酯、低密度脂蛋白水平较治疗前均下降,且观察组低于对照组,高密度脂蛋白水平较治疗前升高,且观察组高于对照组,差异均有显著性(P<0.05)。两组患者治疗期间不良反应总发生率差异无显著性(P>0.05),随访期间主要不良心血管事件及出血事件总发生率差异均无显著性(P>0.05)。结论西洛他唑联合替格瑞洛对老年急性心肌梗死患者的超敏C反应蛋白、脂蛋白(a)及心功能、血脂水平等均有显著改善作用,且用药安全,值得临床推广。
Objective To explore the value of cilostazol combined with ticagrelor in elderly patients with AMI.Method 80 elderly patients with AMI treated in Jinqiu Hospital from June 2020 to June 2021 were randomly divided into observation group and control group,with 40 cases in each group.All patients were treated with PCI and ticagrelor.The control group was treated with aspirin and the observation group was treated with cilostazol.The cardiac function indexes(LVEDD,LVESD,LVEF hs-CRP,LP(a)),and blood lipid indexes(TC,TG,LDL,HDL)were compared between the two groups before and after treatment,and the adverse reactions and MACE were compared between the two groups occurrence of bleeding events.Result After treatment,LVEDD and LVESD of the two groups were significantly lower than those before treatment,and LVEF was significantly higher than those before treatment(P<0.05).After treatment,LVEDD and LVESD in the observation group were significantly lower than those in the control group,and LVEF was significantly higher than those in the control group(P<0.05).The levels of hs-CRP and LP(a)in the two groups after treatment were significantly lower than those before treatment(P<0.05).After treatment,the levels of hs-CRP and LP(a)in the observation group were significantly lower than those in the control group(P<0.05).After treatment,the levels of TC,TG and LDL in the two groups were significantly lower than those before treatment,and the levels of HDL were significantly higher than those before treatment(P<0.05).After treatment,the levels of TC,TG and LDL in the observation group were significantly lower than those in the control group,and the level of HDL was significantly higher than those in the control group(P<0.05).The total incidence of adverse reactions in the observation group was compared with that in the control group(P>0.05).The total incidence of mace and bleeding events in the observation group were compared with those in the control group(P>0.05).Conclusion Cilostazol combined with tigritol can significantly improve the levels of hs-CRP,LP(a),cardiac function and blood lipid in elderly patients with AMI,and the drug is safe and worthy of clinical promotion.
作者
薛叶
丁栗
裴丽峰
韩英
Xue Ye;Ding Li;Pei Lifeng;Han Ying(Department of Cardiology,Jinqiu Hospital of Liaoning Province,Liaoning Shenyang 110016,China)
出处
《中国医刊》
CAS
2022年第11期1189-1193,共5页
Chinese Journal of Medicine
基金
辽宁省科学技术计划(20180550090)。
作者简介
通信作者:韩英,E-mail:hanyingaa@126.com。
